Tags

Type your tag names separated by a space and hit enter

The role of endocannabinoid system blockade in the treatment of the metabolic syndrome.
J Clin Pharmacol. 2007 May; 47(5):642-52.JC

Abstract

This review considers the use of the first selective blocker of the cannabinoid receptor type 1, rimonabant, to reduce weight and improve cardiovascular disease risk factors in obese patients with metabolic syndrome or multiple cardiovascular disease risk factors. In 4 large trials-Rimonabant in Obesity (RIO)-Lipids, RIO-Europe, RIO-North America, and RIO-Diabetes-after 1 to 2 years of treatment, rimonabant (20 mg/day) led to a significantly greater weight loss and reduction in waist circumference compared with placebo. Treatment with rimonabant was also associated with other favorable changes, including better glycemic control in type 2 diabetes mellitus, improved lipid profile, reduced blood pressure, increased adiponectin levels, fall in high-sensitivity C-reactive protein concentrations, and an overall decrease in the prevalence of the metabolic syndrome. Initial experience with rimonabant shows that it is generally well tolerated with the most common side effect of mild nausea. Rimonabant may be a useful adjunct to lifestyle and behavior modification in the treatment of obese subjects with metabolic syndrome or multiple cardiometabolic risk factors.

Authors+Show Affiliations

FFPM, FRCP, FRCPath, Department of Clinical Biochemistry, Royal Free Hospital, Royal Free University College School of Medicine, Pond Street, London NW3 2QG, United Kingdom.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

17392496

Citation

Kakafika, Anna I., et al. "The Role of Endocannabinoid System Blockade in the Treatment of the Metabolic Syndrome." Journal of Clinical Pharmacology, vol. 47, no. 5, 2007, pp. 642-52.
Kakafika AI, Mikhailidis DP, Karagiannis A, et al. The role of endocannabinoid system blockade in the treatment of the metabolic syndrome. J Clin Pharmacol. 2007;47(5):642-52.
Kakafika, A. I., Mikhailidis, D. P., Karagiannis, A., & Athyros, V. G. (2007). The role of endocannabinoid system blockade in the treatment of the metabolic syndrome. Journal of Clinical Pharmacology, 47(5), 642-52.
Kakafika AI, et al. The Role of Endocannabinoid System Blockade in the Treatment of the Metabolic Syndrome. J Clin Pharmacol. 2007;47(5):642-52. PubMed PMID: 17392496.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The role of endocannabinoid system blockade in the treatment of the metabolic syndrome. AU - Kakafika,Anna I, AU - Mikhailidis,Dimitri P, AU - Karagiannis,Asterios, AU - Athyros,Vasilios G, Y1 - 2007/03/28/ PY - 2007/3/30/pubmed PY - 2007/7/31/medline PY - 2007/3/30/entrez SP - 642 EP - 52 JF - Journal of clinical pharmacology JO - J Clin Pharmacol VL - 47 IS - 5 N2 - This review considers the use of the first selective blocker of the cannabinoid receptor type 1, rimonabant, to reduce weight and improve cardiovascular disease risk factors in obese patients with metabolic syndrome or multiple cardiovascular disease risk factors. In 4 large trials-Rimonabant in Obesity (RIO)-Lipids, RIO-Europe, RIO-North America, and RIO-Diabetes-after 1 to 2 years of treatment, rimonabant (20 mg/day) led to a significantly greater weight loss and reduction in waist circumference compared with placebo. Treatment with rimonabant was also associated with other favorable changes, including better glycemic control in type 2 diabetes mellitus, improved lipid profile, reduced blood pressure, increased adiponectin levels, fall in high-sensitivity C-reactive protein concentrations, and an overall decrease in the prevalence of the metabolic syndrome. Initial experience with rimonabant shows that it is generally well tolerated with the most common side effect of mild nausea. Rimonabant may be a useful adjunct to lifestyle and behavior modification in the treatment of obese subjects with metabolic syndrome or multiple cardiometabolic risk factors. SN - 0091-2700 UR - https://www.unboundmedicine.com/medline/citation/17392496/The_role_of_endocannabinoid_system_blockade_in_the_treatment_of_the_metabolic_syndrome_ L2 - https://doi.org/10.1177/0091270007299358 DB - PRIME DP - Unbound Medicine ER -